ReviewCancers2020
Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05729464 (Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- The Role of Anticoagulation on Venous Thromboembolism Primary Prophylaxis in Low- to Intermediate-Risk Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.Blood advances · 2020Pooled it
- D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.The oncologist · 2020Trial
- Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study.The oncologist · 2025Observational
- A Single-Institution Audit of Chemo-PORT Placements During Breast Surgery with Literature Review for Management of Common Complications.Indian journal of surgical oncology · 2025Article
- Cancer-associated venous thromboembolism: a comprehensive review.Thrombosis journal · 2025Review
- A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers.Journal of thrombosis and thrombolysis · 2023Article
- Implementing guidelines to prevent cancer associated thrombosis: how can we do better?Research and practice in thrombosis and haemostasis · 2023Review
- Primary thromboprophylaxis in not surgically treated intra-luminal gastrointestinal cancer (ILGC) treated with first-line chemotherapy: A single institution preliminary safety report.SAGE open medical case reports · 2023Article
- Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.Blood advances · 2022Article
- Pulmonary embolism at autopsy in cancer patients.Journal of thrombosis and haemostasis : JTH · 2021Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to treat and the risk of bleeding. Two recent trials demonstrated that the number needed to treat can be reduced by selecting cancer patients at high risk for VTE with prediction scores, leading the latest guidelines to suggest such an approach in clinical practice. Yet, the interpretation of these trial results and the translation of the guideline recommendations to clinical practice may be less straightforward. In this clinically-oriented review, some of the controversies are addressed by focusing on the burden of VTE in cancer patients, discussing the performance of available risk assessment scores, and summarizing the findings of recent trials. This overview can help oncologists, hematologists, and vascular medicine specialists decide about thromboprophylaxis in ambulatory cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.